Kancera CEO Thomas Olin Discusses Kand567 Phase 2 Studies for COVID-19 and Acute Myocardial Infarction | Dr. Thomas Olin, CEO , Kancera AB. 00:10:00
Dr. Thomas Olin is associated with Kancera AB, a Swedish pharmaceutical company headquartered at the Karolinska Institute Science Park in Stockholm. The company specializes in developing small-molecule drug candidates aimed at controlling disease-promoting immune and cancer cells, with a particular focus on the fractalkine axis. Dr. Olin has been a significant figure in the company, contributing to its leadership and direction since its foundation in 2010. Under his tenure, Kancera has advanced several drug candidates from preclinical discovery to clinical development.
